Amylyx Pharmaceuticals (AMLX) Exchange Rate Effect (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Exchange Rate Effect of -$111000.0 for Q1 2026, down 156.35% year-over-year from $197000.0 in Q1 2025, and down 194.07% quarter-over-quarter from $118000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Exchange Rate Effect (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Exchange Rate Effect history runs 6 years deep, the most recent figure standing at -$111000.0 for Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 156.35% year-over-year to -$111000.0; the TTM figure through Mar 2026 stood at $766000.0 (up 684.73% YoY), while the FY2025 annual figure was $1.1 million, up 345.21% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at -$111000.0, down from $118000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $608000.0 in Q2 2025, with the low at -$525000.0 in Q4 2024.
- The 5-year median for Exchange Rate Effect is -$18000.0 (2023), against an average of $36470.6.
- Peak annual rise in Exchange Rate Effect reached 5533.33% in 2022, while the deepest fall reached 18550.0% in 2022.
- Amylyx Pharmaceuticals' Exchange Rate Effect stood at $507000.0 in 2022, then slumped by 53.25% to $237000.0 in 2023, then sank by 321.52% to -$525000.0 in 2024, then surged by 122.48% to $118000.0 in 2025, then sank by 194.07% to -$111000.0 in 2026.
- Business Quant data shows AMLX's Exchange Rate Effect at -$111000.0 in Q1 2026, $118000.0 in Q4 2025, and $151000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -5.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | -7.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 39.87 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -3.30 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.39 Bn | 4.39 Bn | - | -68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -68,000.00 |
| Jun 30, 2026 | -68,000.00 |
| Mar 31, 2026 | -111,000.00 |
| Mar 31, 2026 | -111,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 608,000.00 |
| Jun 30, 2025 | 608,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Dec 31, 2024 | -525,000.00 |
| Dec 31, 2024 | -525,000.00 |
| Sep 30, 2024 | 236,000.00 |
| Sep 30, 2024 | 236,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | -110,000.00 |
| Mar 31, 2024 | -110,000.00 |